Graft Versus Host Disease Treatment Market to Grow with a CAGR of 8.06% through 2028
Substantial investment in research and development,
and the adoption of personalized medicine approaches are expected to drive the
Global Graft Versus Host Disease Treatment Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Graft Versus
Host Disease Treatment Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Graft
Versus Host Disease Treatment Market stood at USD 1.76 billion in 2022 and is
anticipated to grow with a CAGR of 8.06% in the
forecast period, 2024-2028. This can be attributed to increasing investment in
research and development. Pharmaceutical companies and research institutions
are dedicating substantial resources to GVHD research and development. The
desire to discover safer and more effective treatments has led to a surge in
clinical trials and collaborative efforts aimed at finding innovative
solutions. The prospect of breakthrough therapies has attracted both public and
private investment. Furthermore, an increased focus on supportive care and
patient quality of life is evident in the GVHD treatment landscape.
Multidisciplinary care teams are addressing the physical, emotional, and
psychosocial needs of GVHD patients. This holistic approach aims to enhance the
overall well-being of individuals undergoing treatment.
The market's
growth rate was significantly impacted by the COVID-19 pandemic.
Graft-versus-Host disease (GvHD) is a condition that arises in individuals who
have undergone allogeneic transplantation, where the donor's immune cells
attack the recipient's organs, triggering a "cytokine storm." This
term refers to the excessive production of inflammatory cytokines, which can
lead to local organ damage. A review published in Nature in April 2021
highlighted a similar phenomenon in COVID-19 cases, where infected individuals
experience heightened levels of inflammatory cytokines, resulting in organ
failure. Consequently, GvHD severity increases when a patient is also affected
by COVID-19. This complication surge presented a significant challenge to the
global healthcare system during the pandemic. Consequently, there was a spike
in demand for GvHD treatment products to address the additional complications
arising from COVID-19. Moreover, in the current post-COVID-19 scenario, with
global restrictions easing and disease screening services resuming, market
growth is stabilizing.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Graft Versus Host Disease Treatment Market.”
The market is expected to experience continued growth
throughout the analysis period due to factors such as the rising utilization of
bone marrow or hematopoietic stem cell treatments, the increasing incidence of
acute GvHD, and the growing number of pipeline drugs. For instance, a report
from StatPearls Publishing in October 2021 revealed that the incidence of acute
GvHD was approximately 50% in patients receiving HCT from HLA-matched siblings,
with even higher rates in unmatched donor scenarios. The incidence of chronic
GvHD ranged from 6% to 80%. Additionally, an article published by Elsevier in
June 2021 stated that in the United States, 42% of patients developed chronic
GvHD within three years of allogenic HCT, with 66% of those individuals having
previously experienced acute GvHD. The treatment-resistant nature of chronic
GvHD is expected to drive growth in the GvHD treatment market.
Substantial investments in research and development by
industry players and governments are anticipated to create attractive
opportunities in the market. For example, in June 2021, Equillium Inc. reported
the successful completion of an End-of-Phase 1 meeting with the US FDA for
itolizumab as a first-line treatment for patients with acute graft-versus-host
disease (aGvHD). Consequently, positive outcomes from such clinical trials are
likely to lead to new treatments, which are expected to bolster market growth
over the forecast period.
The Global Graft Versus Host Disease Treatment Market
is segmented into disease type, product, distribution channel, regional
distribution, and company. Based on its product,
the corticosteroids segment in the Graft-versus-Host disease treatment market
is poised for significant expansion. This growth is driven by several key
factors, including the increasing prevalence of the target disease and a rising
number of research initiatives. Over the projected period, we anticipate
substantial growth in the corticosteroids segment due to heightened research
and development efforts focused on corticosteroid treatments and their
combinations for addressing Graft-versus-Host disease in hematopoietic cell
transplantation (HCT) patients. A July 2021 article published by the National
Library of Medicine highlighted the lack of effective second-line treatments
for patients with steroid-refractory chronic graft-versus-host disease,
underscoring the considerable scope for research to contribute to the expansion
of the Graft-versus-Host disease treatment market.
Based on distribution channel, Hospital pharmacies are
expected to continue dominating the Global Graft Versus Host Disease Treatment
Market and maintain their stronghold throughout the forecast years for several
compelling reasons. Firstly, hospitals serve as the primary point of care for
patients undergoing hematopoietic cell transplantation (HCT), the procedure
most commonly associated with graft-versus-host disease (GvHD). As a result,
these healthcare facilities have the infrastructure, expertise, and resources
to provide comprehensive GvHD treatment, including access to a wide range of
pharmaceuticals. Secondly, hospital pharmacies are integral in ensuring the
timely and consistent administration of medications, which is crucial in
managing GvHD effectively. Additionally, the collaborative approach within
hospitals, involving multidisciplinary teams of physicians, pharmacists, and
nurses, enables a holistic and patient-centered treatment approach. Lastly, the
continuous advancements in GvHD therapies and the introduction of novel
pharmaceuticals are more readily integrated into hospital protocols, allowing
these pharmacies to adapt quickly to evolving treatment options. All these
factors combine to reinforce the dominance of hospital pharmacies in the Global
GvHD Treatment Market, promising their continued leadership in the years to
come.
Major companies operating in Global Graft Versus
Host Disease Treatment Market are:
- Pfizer Inc
- Sanofi SA
- Astellas Pharma Inc
- Incyte Corp
- AbbVie Inc
- Bristol-Myers Squibb Co
- F Hoffmann-La Roche AG
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global Graft Versus Host Disease Treatment Market
is entering an exciting phase characterized by personalized medicine, targeted
therapies, early detection strategies, improved conditioning regimens,
regenerative medicine, and enhanced supportive care. These trends hold the
promise of transforming the landscape of GVHD treatment, ultimately leading to
better outcomes and improved quality of life for patients. As research and
innovation continue to advance, it is essential for stakeholders across the healthcare
spectrum to embrace these trends and work collaboratively to address the
complex challenges posed by GVHD,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Graft Versus Host Disease Treatment Market By Disease
Type (Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease), By
Product (Corticosteroids, Monoclonal Antibodies, Tyrosine Kinase Inhibitors),
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Graft Versus Host Disease Treatment Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Graft Versus Host Disease Treatment Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com